ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Revisiting the SUMMIT Trial | JACC Deep Dive"
Episode Synopsis
This JACC Deep Dive in our May 13 issue highlights new findings from the SUMMIT CKD study, showing that terzepatide improves symptoms, function, and weight in patients with HFpEF and obesity—regardless of kidney function. The analysis also underscores the importance of using both creatinine and cystatin C to better assess kidney health. Reviewers praised the study's methodological rigor and dual focus, while noting the need for larger, long-term trials to confirm renal outcomes.
More episodes of the podcast JACC This Week
December 2, 2025: Global CVD 1990–2023: Trends, Risks, and the Road Ahead | JACC This Week
24/11/2025
November 18, 2025: Adiposity, Heart Failure, and the Future of Cardiometabolic Care | JACC This Week
10/11/2025
November 11, 2025: Precision, Place, and the Future of Cardiovascular Prediction | JACC This Week
03/11/2025
In God we trust